natgillin/translations-raw huggingface dataset:
The use of Prevomax solution for injection against vomiting due to motion sickness is not recommended.
Ne preporučuje se upotreba Prevomax otopine za injekciju za sprječavanje povraćanja uzrokovanog bolešću putovanja.
• For the prevention of vomiting and the reduction of nausea, except that induced by motion sickness.
• Za sprječavanje povraćanja i smanjenje mučnine, osim kad je uzrok bolest kretanja.
The bioavailability of maropitant after subcutaneous administration in cats was 91.3%.
Bioraspoloživost maropitanta nakon supkutane primjene u mačaka bila je 91,3 %.
Following a single intravenous dose at 1 mg/kg the initial plasma concentration was 363 ng/ml.
Nakon jedne intravenske doze od 1 mg/kg, početna koncentracija u plazmi iznosila je 363 ng/ml.
To prevent vomiting, Prevomax solution for injection should be administered more than 1 hour in advance.
Za sprječavanje povraćanja, Prevomax otopinu za injekciju treba davati 1 sat unaprijed.
Shelf life after first opening the vial: 56 days.
Rok valjanosti poslije prvog otvaranja bočice: 56 dana.
The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to cats was characterised by a maximum concentration (Cmax) in plasma of approximately 165 ng/ml; this was achieved on average 0.32 hours (19 min) post-dosing (Tmax).
Farmakokinetički profil maropitanta kada se primjenjuje u mačaka kao jednokratna supkutana doza od 1 mg/kg tjelesne težine karakterizira maksimalna koncentracija (Cmax) u plazmi od otprilike 165 ng/ml, a ta se koncentracija postigne u prosjeku za 0,32 sata (19 min) nakon primjene doze (Tmax).
Maropitant is metabolised in the liver and therefore should be used with caution in patients with hepatic disease.
Maropitant se metabolizira u jetri pa je stoga potreban oprez kad se daje životinjama s bolešću jetre.
Dechra Veterinary Products Ltd. Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS United Kingdom Tel.: +44 (0)1939 211200
Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS United Kingdom Tel.: +44 (0)1939 211200
The pharmacokinetic profile of maropitant when administered as a single subcutaneous dose of 1 mg/kg body weight to dogs was characterised by a maximum concentration (Cmax) in plasma of approximately 92 ng/ml; this was achieved within 0.75 hours post-dosing (Tmax).
Farmakokinetički profil maropitanta, kada je primijenjen u pasa kao jednokratna supkutana doza od 1 mg/kg tjelesne težine, karakterizira maksimalna koncentracija (Cmax) u plazmi od otprilike 92 ng/ml, koja se postiže unutar 0,75 sati nakon primjene doze (Tmax).
STATEMENT OF ACTIVE SUBSTANCES 10 mg/ml maropitant
SASTAV DJELATNIH TVARI 10 mg/ml maropitant
Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t1/2) of 8.84 hours.
Nakon maksimalnih koncentracija slijedilo je smanjenje sustavne izloženosti s prividnim poluvremenom eliminacije (t1/2) od 8,84 sata.
The efficacy of maropitant in reduction of nausea was demonstrated in studies using a model (xylazine-induced nausea).
Djelotvornost maropitanta za smanjivanje mučnine dokazana je u ispitivanjima u kojima je korišten model (mučnina izazvana ksilazinom).
Peak concentrations were followed by a decline in systemic exposure with an apparent elimination half-life (t1/2) of 16.8 hours.
Nakon maksimalnih koncentracija slijedilo je smanjenje sustavne izloženosti s prividnim poluvremenom eliminacije (t1/2) od 16,8 sata.
Following a single intravenous dose at 1 mg/kg the initial plasma concentration was 1040 ng/ml.
Nakon jedne intravenske doze od 1 mg/kg, početna koncentracija u plazmi iznosila je 1040 ng/ml.
The volume of distribution at steady-state (Vss) was 9.3 l/kg and systemic clearance was 1.5 l/h/kg.
Volumen distribucije u stabilnom stanju (Vss) bio je 9,3 l/kg, a sustavni klirens 1,5 l/h/kg.
Apart from transient reactions at the injection site following subcutaneous administration, maropitant was well tolerated in dogs and young cats injected daily with up to 5 mg/kg (5 times the recommended dose) for 15 consecutive days (3-times the recommended duration of administration).
Osim prolaznih reakcija na mjestu supkutane primjene, psi i mlade mačke dobro podnose maropitant u dnevnoj dozi do 5 mg/kg (peterostruka preporučena doza) tijekom 15 uzastopnih dana (trostruka preporučena duljina trajanja primjene).
Renal and faecal clearances are minor routes of elimination for maropitant, with less than 1% of a 1 mg/kg subcutaneous dose appearing in the urine or faeces as maropitant.
Izlučivanje putem bubrega i fecesa manje je značajan put eliminacije maropitanta pa se pri supkutanoj dozi od 1 mg/kg u urinu ili fecesu pojavi manje od 1 % maropitanta.
QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains:
KVALITATIVNI I KVANTITATIVNI SASTAV 1 ml sadrži: Djelatna tvar: maropitant
Increases of approximately 10% in the QT interval of the ECG were observed in a study on healthy Beagle dogs administered 8 mg/kg orally; however, such an increase is unlikely to be of clinical significance.
Povećanje QT intervala od otprilike 10 % zabilježeno je kod pretrage EKG-om, u ispitivanju provedenom na zdravim psima pasmine bigl, koji su primili peroralnu dozu od 8 mg/kg.
United Kingdom Dechra Veterinary Products Ltd. Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS Tel.: +44 (0)1939 211200
Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS Tel.: +44 (0)1939 211200
The safety of maropitant has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, or in pregnant or lactating dogs and cats.
Neškodljivost maropitanta nije utvrđena kod pasa mlađih od 8 tjedana ili kod mačaka mlađih od 16 tjedana te kod gravidnih i dojnih kuja i mačaka.
Intravenous administration of the veterinary medicinal product should be given as a single bolus without mixing the product with any other fluids.
Veterinarsko-medicinski proizvod treba intravenski primijeniti kao jednu bolus injekciju bez miješanja s bilo kakvim drugim tekućinama.
METHOD AND ROUTE(S) OF ADMINISTRATION SC, IV
NAČIN I PUT(EVI) PRIMJENE s.c., i.v.
The safety of maropitant has not been established in dogs less than 8 weeks of age, or in cats less than 16 weeks of age, and in pregnant or lactating dogs and cats.
Neškodljivost maropitanta nije utvrđena kod pasa mlađih od 8 tjedana i kod mačaka mlađih od 16 tjedana te kod gravidnih i dojnih kuja i mačaka.
Following repeated subcutaneous administration of once-daily doses of 1 mg/kg bodyweight for five consecutive days, accumulation was 250%.
Nakon ponovljene supkutane primjene dozea od 1 mg/kg tjelesne težine, jednom dnevno, tijekom pet uzastopnih dana, akumulacija je iznosila 250 %.
The veterinary medicinal product solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg of maropitant / kg bodyweight (1 ml/10 kg bodyweight) for up to 5 consecutive days.
Veterinarsko-medicinski proizvod, otopinu za injekciju treba primjenjivati supkutano ili intravenski jednom dnevno u dozi od 1 mg maropitanta po kg tjelesne težine (1 ml/10 kg tjelesne težine) do 5 uzastopnih dana.
Prevomax solution for injection should be injected subcutaneously or intravenously, once daily, at a dose of 1 mg of maropitant/kg body weight (1 ml/10 kg body weight).
Prevomax otopinu za injekciju treba primjenjivati supkutano ili intravenski, jednom dnevno u dozi od 1 mg maropitanta / kg tjelesne težine (1 ml / 10 kg tjelesne težine) do 5 uzastopnih dana.
Dechra Veterinary Products S.L.U.
Dechra Veterinary Products Ltd.
Pain at injection site may occur when injected subcutaneously.
Prilikom supkutane primjene može se pojaviti bol na mjestu injiciranja.
Intravenous administration of Prevomax should be given as a single bolus without mixing the product with any other fluids.
Intravenska primjena Prevomax treba biti u obliku jedne bolus injekcije bez miješanja s nekim drugim tekućinama.
Maropitant displays linear kinetics when administered subcutaneously within the 0.25-3 mg/kg dose range.
Kada se daje supkutano, maropitant pokazuje linearnu kinetiku unutar raspona doze od 0,25-3 mg/kg.
Maropitant displays linear kinetics when administered subcutaneously within the 0.5-2 mg/kg dose range.
Kada se daje supkutano, maropitant pokazuje linearnu kinetiku unutar raspona doze od 0,5-2 mg/kg.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) 1 ml contains:
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH SASTOJAKA 1 ml sadrži: Djelatna tvar: maropitant
5.2 Pharmacokinetic particulars
Farmakokinetički podaci
WITHDRAWAL PERIOD(S)
Razdoblje(a) karencije
NAME OF THE VETERINARY MEDICINAL PRODUCT Prevomax 10 mg/ml injection maropitant
Prevomax 10 mg/ml injekcija maropitant
Česká republika Sevaron ltd Palackeho trida 163 a 61200 Brno Tel. +420 541 426 370
Palackeho trida 163 a 61200 Brno Tel.
ROUTE(S) OF ADMINISTRATION SC, IV
PUT(EVI) PRIMJENE s.c., i.v.
NAME OF THE VETERINARY MEDICINAL PRODUCT Prevomax 10 mg/ml solution for injection for dogs and cats
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Prevomax 10 mg/ml otopina za injekciju za pse i mačke
PACKAGE LEAFLET: Prevomax 10 mg/ml solution for injection for dogs and cats
UPUTA O VMP-u: Prevomax 10 mg/ml otopina za injekciju za pse i mačke
NAME OF THE VETERINARY MEDICINAL PRODUCT Prevomax 10 mg/ml solution for injection for dogs and cats maropitant
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Prevomax 10 mg/ml otopina za injekciju za pse i mačke maropitant
The elimination t1/2 following intravenous dosing was approximately 4.9 h. There appears to be an age-related effect on the pharmacokinetics of maropitant in cats with kittens having higher clearance than adults.
Izgleda da je farmakokinetički učinak maropitanta povezan sa starošću mačaka jer je u mačića klirens veći nego u odraslih mačaka.
PHARMACEUTICAL FORM Solution for injection A clear, colourless to light yellow solution
Bistra, bezbojna do svijetložuta otopina.
Maropitant
NUSPOJAVE
Optimal treatment duration is not yet established.
Do sada nije ustanovljeno optimalno trajanje liječenja.
There were no differences in response rates between the two dose groups.
Nije bilo razlika u stopama odgovora između dvije dozirne skupine.
Longer duration of the treatment (> 36 months) may delay the onset of further recurrences; however the impact of this finding on the overall survival remains unknown.
Duže trajanje liječenja (>36 mjeseci) može odgoditi pojavu dodatnih recidiva; međutim utjecaj tih nalaza na ukupno preživljenje ostaje nepoznat.
No conclusions can be drawn for other less common mutation subgroups due to the low number of observed events.
Nikakav zaključak se ne može izvući za druge manje česte podskupine mutacija zbog malog broja opaženih događaja.
The safety database for children with Ph+ALL is very limited though no new safety
Baza sigurnosnih podataka za djecu s Ph+ALL vrlo je ograničena iako nisu uočena nikakva nova sigurnosna pitanja.
Follow all your doctor's instructions carefully, even if they differ from the general information contained in
Pažljivo slijedite sve upute dobivene od liječnika, čak i onda ako se razlikuju od općih informacija
The remaining circulating radioactivity consisted of a number of minor metabolites.
Preostala se cirkulirajuća radioaktivnost sastojala od određenog broja manje važnih
Tumours were required to be measurable in at least one site of disease, and response characterisation based on Southwestern Oncology Group (SWOG) criteria.
Za tumore je bilo potrebno da se mogu mjeriti na barem jednom mjestu bolesti, a karakterizacija odgovora bila je temeljena na kriterijima grupacije Southwestern Oncology Group (SWOG).
Table 5 Best tumour response in trial STIB2222 (GIST)
Tablica 5 Najbolji tumorski odgovor u ispitivanju STIB2222 (GIST)
* Full follow-up period; NE - Not estimable
* Potpuni period praćenja; NP - nije moguće procijeniti
Mitotic index data were available for 556 of the 713 intention-to-treat (ITT) population.
Podaci o mitotskom indeksu su bili dostupni za 556 od 713 bolesnika u populaciji planiranoj za liječenje (ITT - engl. intention-to-treat).
If you are not able to take the medicine as your doctor prescribed or you feel you do not need it anymore, contact your doctor straight
Ako niste u mogućnosti uzimati ovaj lijek kako Vam je liječnik propisao ili ako osjećate da Vam više ne treba, odmah se obratite svom liječniku.
Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.
Bolesnici s niskim ili vrlo niskim rizikom od recidiva ne bi trebali primati adjuvantno liječenje.
Older people: Imatinib pharmacokinetics have not been specifically studied in older people.
Starije osobe: Farmakokinetika imatiniba nije specifično ispitivana u starijih osoba.
• Unexpected bleeding or bruising (when you have not hurt yourself).
• Neočekivano krvarenje ili pojava masnica (kada se niste ozlijedili).
It arises from uncontrolled cell growth of the supporting tissues of these organs.
Nastaje zbog nekontroliranog rasta stanica potpornog tkiva tih organa.
A significant number of patients who had stable disease at the time of the interim analysis achieved a partial response with longer treatment (median follow-up 31 months).
Značajan broj bolesnika koji je imao stabilnu bolest u vrijeme interim analize je postigao djelomični odgovor s dužim liječenjem (medijan praćenja od 31 mjeseca).
The median overall survival has not been reached.
Medijan vrijednosti ukupnog preživljenja nije dosegnut.
All doses (n=147) 400 mg (n=73) 600 mg (n=74) n (%)
Sve doze (n=147) 400 mg (n=73) 600 mg (n=74) n (%)
The results of subgroup analyses according to the United States National Institutes of Health (NIH) and the Armed Forces Institute of Pathology (AFIP) risk classifications are shown in Table 6.
Rezultati analize podskupine bolesnika razvrstane prema klasifikacijama rizika američkog Nacionalnog instituta za zdravstvo (NIH - National Institutes of Health) i Instituta za patologiju američkih oružanih snaga (AFIP - Armed Forces Institute of Pathology) su prikazani u Tablici 6.
Therefore, the use of imatinib in combination requires special precaution.
Stoga primjena imatiniba u kombinaciji zahtijeva posebne mjere
No benefit was observed in the low and very low risk groups.
U skupinama s niskim ili vrlo niskim rizikom nije uočena korist.
A major response combines both complete and partial responses: complete (0% Ph+ metaphases),
Veliki odgovor je kombinacija potpunih i djelomičnih odgovora: potpuni (0% Ph+ metafaza),
However, these associations are not sufficiently pronounced to warrant dose adjustment.
No, te veze nisu dovoljno izražene da bi opravdale prilagođavanje doze.
Haematological experts in the management of this disease should supervise the therapy throughout all phases
Specijalisti hematolozi uključeni u liječenje ove bolesti trebaju nadzirati terapiju kroz sve faze
Your doctor has prescribed Imatinib Teva B.V. because you suffer from a serious condition.
Vaš liječnik je propisao Imatinib Teva B.V., jer patite od ozbiljnog stanja.
GIST is a cancer of the stomach and bowels.
GIST je rak želuca i crijeva.
• Recurrence (reactivation) of hepatitis B infection when you have had hepatitis B in the past (a liver
• Ponovna pojava (ponovna aktivacija) infekcije virusom hepatitisa B ako ste u prošlosti imali hepatitis B (infekciju jetre).
Pharmacotherapeutic group: Protein kinase inhibitors, ATC code: L01XE01
Farmakoterapijska skupina: Inhibitori protein kinaze, ATK oznaka: L01XE01
2031GA Haarlem Netherlands
2031 GA Haarlem
The daily dose was escalated to 800 mg in a total of 103 patients; 6 patients achieved a partial response and 21 stabilisation of their disease after dose escalation for an overall clinical benefit of 26%.
Dnevna doza je povećana na 800 mg kod ukupno 103 bolesnika; 6 bolesnika je postiglo djelomični odgovor, a 21 stabilizaciju njihove bolesti nakon povećanja doze, uz ukupnu kliničku korist od 26%.
Decreased values of albumin caused a reduced clearance (CL/f); and higher levels of WBC led to a reduction of CL/f.
Smanjene vrijednosti albumina uzrokovale su smanjeni klirens (CL/f); a više WBC razine su dovele do smanjenja CL/f vrijednosti.
Length of treatment in the clinical trial supporting this indication was 36 months (see section 5.1).
Duljina liječenja u kliničkom ispitivanju vezanom uz ovu indikaciju bila je 36 mjeseci (vidjeti dio 5.1).
However if it is nearly time for the next dose, - Then continue with your normal schedule.
Međutim, ako je uskoro vrijeme za sljedeću dozu, preskočite propuštenu dozu.
The safety and efficacy of imatinib in children with MDS/MPD, DFSP, GIST and HES/CEL aged less than 18 years of age have not been established in clinical trials.
Sigurnost i djelotvornost imatiniba u djece s MDS/MPB-om, DFSP-om, GIST-om i HES/KEL-om mlađe od 18 godina nisu ustanovljene u kliničkim ispitivanjima.
Some children and adolescents taking Imatinib Teva B.V. may have slower than normal growth.
Kod neke djece i adolescenata koji uzimaju Imatinib Teva B.V. rast može biti sporiji od normalnog.
8 to 10 g (single dose): Vomiting and gastrointestinal pain have been reported.
8 g do 10 g (jednokratna doza): zabilježeni su povraćanje i bolovi u trbuhu.
The amount of Imatinib Teva B.V. given will depend on your child's condition, body weight and height.
Količina Imatiniba Teva B.V.koju je potrebno dati ovisiti će o stanju djeteta, tjelesnoj težini i visini.
All treatment regimens include administration of steroids for CNS prophylaxis.
Svi terapijski protokoli uključuju primjenu steroida radi profilakse CNS-a.
The risk of recurrence in patients after surgery of their primary GIST was retrospectively assessed based on the following prognostic factors: tumour size, mitotic index, tumour location.
Rizik od recidiva bolesti u bolesnika nakon kirurškog uklanjanja primarnog GIST-a je retrospektivno procijenjen na temelju sljedećih prognostičkih faktora: veličina tumora, mitotski indeks, lokacija tumora.
All patients received imatinib and consolidation chemotherapy (see Table 3) after induction and the levels of bcr-abl transcripts were identical in the two arms at 8 weeks.
Svi su bolesnici primili imatinib i konsolidacijsku kemoterapiju (vidjeti Tablicu 3) nakon indukcije, a razine bcr-abl prijepisa bile su identične u oba kraka nakon 8 tjedana.
In all clinical studies 38-40% of patients were ≥ 60 years of age and 10-12% of patients were ≥ 70 years of
U svim kliničkim ispitivanjima 38-40 % bolesnika bilo je u dobi ≥60 godina, a 10-12% bolesnika bilo je u dobi ≥70 godina.
Non-neoplastic lesions not identified in earlier preclinical studies were the cardiovascular system, pancreas, endocrine organs and teeth.
Neneoplastičke lezije koje nisu identificirane u prethodnim pretkliničkim ispitivanjima javile su se u kardiovaskularnom sustavu, gušterači, endokrinim organima i zubima.
12 months 24 months
24 mjeseci
The risk of recurrence was thus reduced by approximately 89% as compared with placebo (hazard ratio = 0.113 [0.049-0.264]).
Rizik od recidiva bolesti je smanjen za otprilike 89% u usporedbi s placebom (omjer rizika = 0,113 [0,049-0,264]).
If you have any questions about how Imatinib Teva B.V. works or why this medicine has been prescribed for you, ask your doctor.
Ako imate bilo kakvih pitanja o tome na koji način djeluje Imatinib Teva B.V., ili zašto je taj lijek Vama propisan, obratite se svom liječniku.
In 61 of these 117 patients FIP1L1-PDGFRα fusion kinase was identified.
U 61 od tih 117 bolesnika identificirana je fuzijska kinaza FIP1L1-PDGFRα.
The effect of stopping treatment after achieving a response has not been investigated.
Učinak prekida liječenja nakon postizanja odgovora nije ispitivan.
Women of childbearing potential must be advised to use effective contraception during treatment.
Žene reproduktivne dobi treba savjetovati da koriste učinkovitu kontracepciju tijekom liječenja.
At the time of analysis, the treatment duration was a median of 7 months (7 days to 13 months).
U vrijeme provođenja analize, medijan trajanja liječenja iznosio je 7 mjeseci (7 dana do 13 mjeseci).
Name and address of the manufacturers responsible for batch release Teva Czech Industries s.r.o.
Naziv i adresa proizvođača odgovornih za puštanje serije lijeka u promet Teva Czech Industries s.r.o.
Store below 30°C
Čuvati na temperaturi ispod 30°C.
These patients ranged in age from 18 to 83 years old and had a pathologic diagnosis of Kit-positive malignant GIST that was unresectable and/or metastatic.
Dob se tih bolesnika kretala od 18 do 83 godine, a imali su patološku dijagnozu Kit-pozitivnog malignog GIST-a koji je bio inoperabilan i/ili metastatski.
The median time of follow-up was 54 months (from date of randomisation to data cut-off), with a total of 83 months between the first patient randomised and the cut-off date.
Medijan vremena praćenja bio je 54 mjeseca (od datuma randomizacije do završetka prikupljanja podataka), pri čemu je od randomizacije prvog bolesnika do završetka prikupljanja podataka prošlo 83 mjeseca.
- If you are being treated for HES/CEL:
Ako se liječite zbog HES/KEL-a:
Treatment with imatinib may be interrupted or the dose may be reduced, as recommended in section
Liječenje imatinibom može se prekinuti ili se doza može smanjiti, kao što je preporučeno u dijelu 4.2.
Do not stop taking Imatinib Teva B.V. unless your doctor tells you to.
Nemojte prestati uzimati Imatinib Teva B.V., osim ako Vam to ne kaže liječnik.
C/C, n. 4, Poligono Industrial Malpica
4, Poligono Industrial Malpica
Check with your doctor or pharmacist if you are
Provjerite s liječnikom ili ljekarnikom ako niste sigurni.
Five (5) patients responded, 3 completely and 2 partially.
5 bolesnika je imalo odgovor, 3 kompletni i 2 parcijalni.
If it is used during pregnancy, the patient must be informed of the potential risk to the foetus.
Ako se primjenjuje tijekom trudnoće, bolesnica mora biti informirana o potencijalnom
In children and adolescents, Imatinib Teva B.V. can be used in different phases of the disease (chronic, accelerated phase and blast crisis).
U djece i adolescenata, Imatinib Teva B.V. se može koristiti u različitim fazama bolesti (kronična, ubrzana faza i blastična kriza).
In clinical trials, there was an increased incidence of these events in older people and those with a prior history of cardiac disease.
U kliničkim je ispitivanjima zabilježena povećana incidencija tih događaja u starijih osoba te u onih s anamnezom srčanih bolesti.
The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1).
Iskustvo s imatinibom u bolesnika s MDS/MPB-om povezanim s preuredbom gena za PDGFR je vrlo ograničeno (vidjeti dio 5.1).
Following oral administration in healthy volunteers, the t½ was approximately 18 h, suggesting that oncedaily dosing is appropriate.
Nakon peroralne primjene u zdravih dobrovoljaca, t½ bilo je oko 18 h, što navodi na zaključak da je doziranje jedanput na dan primjereno.
For CML and GIST, your doctor may prescribe a higher or lower dose depending on how you respond to treatment.
Liječnik Vam za KML i GIST može propisati višu ili nižu dozu, ovisno o tome kako reagirate na liječenje.
The most important changes included cardiac hypertrophy and dilatation, leading to signs of cardiac insufficiency in some animals.
Najvažnije promjene uključivale su srčanu hipertrofiju i dilataciju, što je, u nekih životinja, dovelo do znakova srčane
Figure 2 Kaplan-Meier estimates for overall survival (ITT population)
Kaplan-Meierova procjena ukupnog preživljenja (ITT populacija)
The long-term effects of prolonged treatment with imatinib on growth in children are unknown.
Nisu poznati dugoročni učinci produljene terapije imatinibom na rast djece.
Based on preliminary population pharmacokinetic analysis in GIST patients, there were three variables (albumin, WBC and bilirubin) found to have a statistically significant relationship with imatinib pharmacokinetics.
Na temelju preliminarne analize populacijske farmakokinetike u bolesnika s GIST-om, utvrđeno je da tri varijable (albumin, WBC i bilirubin) imaju statistički značajan odnos s farmakokinetikom imatiniba.